However, when NGAL is used as a biomarker for ocular sarcoidosis in the clinical setting, differentiation between PDR from ocular sarcoidosis would be rarely needed because the clinical findings of the two diseases are completely different. This evidence concerns the gene LCN2 and ocular sarcoidosis.